New cocktail of four drugs takes on advanced colorectal cancer
NCT ID NCT07395063
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing a combination of four drugs—irinotecan liposome, capecitabine, bevacizumab, and camrelizumab—as a second or later treatment for people with metastatic colorectal cancer. The study will enroll 68 participants and measure how long the disease stays under control. The goal is to see if this mix can shrink tumors and delay progression.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
irinotecan liposome, capecitabine, bevacizumab, and camrelizumab
What this could lead to
If this works, it could offer a new treatment option for people with metastatic colorectal cancer who have already tried one line of therapy.
What could go wrong
This is a small, early-phase trial with no control group, so results may not be definitive. The combination of drugs may cause significant side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER (CRC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••